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Abstract: Saffron (Crocus sativus L.) and its main constituents, i.e., crocin and crocetin, are natural
carotenoid compounds, which have been reported to possess a wide spectrum of properties and
induce pleiotropic anti-inflammatory, anti-oxidative, and neuroprotective effects. An increasing
number of experimental, animal, and human studies have investigated the effects and mechanistic
pathways of these compounds in order to assess their potential therapeutic use in ocular diseases
(e.g., in age related macular degeneration, glaucoma, and diabetic maculopathy). This narrative
review presents the key findings of published clinical studies that examined the effects of saffron
and/or its constituents in the context of ocular disease, as well as an overview of the proposed
underlying mechanisms mediating these effects.
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1. Introduction
In addition to uncorrected refractive error, age related macular degeneration (AMD), glaucoma,
cataract, and other retinal diseases (e.g., diabetic retinopathy and retinitis pigmentosa) are the
major causes of blindness worldwide [1–4]. Among these ocular diseases, AMD is currently
listed as the leading cause of irreversible vision loss in the developed world [2]. While the
introduction of anti-VEGF (vascular endothelial growth factor) treatment has had a positive impact
on preserving vision and slowing progression in AMD [5], there is still no cure to date. Furthermore,
the increasing prevalence rates of obesity and related cardio-metabolic disease, including type 2
diabetes mellitus (T2DM) and cardiovascular disease (CVD) [6], adds significantly to the imposed
health care burden and increases the treatment challenges. Indeed, increasing data link AMD to
a number of lipid pathway genes, CVD phenotypes, excess body weight, and central/abdominal
obesity [7–9]. Moreover, most of the aforementioned conditions are also associated with aging and
exhibit overlapping pathophysiology with common mechanistic pathways, such as inflammation,
oxidative stress, apoptosis, and neurodegeneration [6,7,10–13]. As these pathways may be affected
by the effects of various nutritional supplements and botanical/herbal compounds (e.g., saffron and
its constituents), increasing research interest is now focused on the potential therapeutic use of such
natural products [11,14–16].
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Saffron is mainly used in cooking as a colouring and flavouring spice that is comprised of
the dried stigmas of the Crocus sativus L. flower, a stemless herb that belongs to the Iridaceae
family [17,18]. Based on phytochemical studies, the pharmacologically active saffron constituents
include bitter principles (e.g., picrocrocin), volatile agents (e.g., safranal, which can be obtained by
picrocrocin hydrolysis), and dye materials (e.g., crocetin and its glycoside, i.e., crocin, which gives
saffron its characteristic colour) [17–19]. In herbal medicine, saffron is traditionally used as
a nerve sedative, stress-reliever, anti-depressant, aphrodisiac, expectorant, and anti-spasmodic
agent [17,18,20,21]. Growing evidence from pharmacological studies has further shown that saffron
or its active constituents may potentially exert neuroprotective, anti-convulsant, anti-depressive,
anxiolytic, anti-oxidant, anti-inflammatory, hypolipidemic, anti-atherogenic, anti-hypertensive,
and even anti-tumour effects [17,18,20,22,23]. Of note, a recent meta-analysis by Pourmasoumi et al.
showed that saffron may be beneficial for several CVD-risk related outcomes (e.g., blood pressure,
body weight, waist circumference, and fasting blood glucose levels), suggesting that saffron may have
protective effects for multiple systemic conditions related to such CVD risk factors [24]. Furthermore,
favourable results have been recently reported from both animal and clinical studies examining the
effects of saffron and its constituents on CVD risk [22,24,25], endothelial function [26], inflammatory
diseases [23,27], oxidative stress [26,28], and glycaemic factors [24,29], indicating that saffron may
have promising potential as adjunct therapy in both systemic conditions and ocular diseases mainly
through its anti-inflammatory and anti-oxidative effects [14,17,20,22].
This narrative review presents key findings of clinical studies that investigated the impact of
saffron or one of its constituents on vision-related outcome measures, and an overview of the proposed
mechanisms mediating these effects. As saffron is a natural product and, hence, saffron supplements
are under less tight regulation regarding sale and dosage, this review is also intended to provide
concise information on dosage and potential side effects based on the available literature.
2. Methods
Although not a systematic review, in order to ensure the quality and consistency of our approach,
in the present narrative review we applied a predefined search strategy and followed, where relevant,
the Preferred Reporting Items for Systematic Reviews (PRISMA) guidelines [30,31].
Search strategy: A systematic search of the following databases was conducted: PubMed, Scopus,
Google Scholar, Cochrane library, and Web of Science. Studies published on these databases available
up to the 31st of January 2019 were included for screening. Using Boolean operators (e.g., AND, OR),
the applied search terms included combinations of the following key words: “saffron”, “safranal”,
“crocetin”, “crocin”, “eye”, “ocular”, “retina”, “diabetes”, “macula”, “glaucoma”, “age related
macular degeneration”, “AMD” “anti-inflammatory”, “anti-oxidant”, “neuroprotective”, “nutrition”,
and “supplement”. Only publications in the English language were included. To minimise the risk of
omitting relevant studies, the reference lists of all eligible papers were also manually checked.
Study selection: After elimination of duplicate records by one author (RH), two authors (RH and
IK) independently reviewed the remaining publications to decide which were suitable for inclusion in
this review. As a first step to eliminate unsuitable studies, all titles and abstracts of the publications
identified through the performed database searches were screened, and studies that were clearly
irrelevant were removed. Subsequently, the remaining papers were evaluated by reviewing the full
text versions. Finally, all clinical studies in adults with ocular diseases which assessed the impact of
saffron and/or its constituents on vision-related outcome measures, such as visual acuity, visual field
parameters, contrast sensitivity, electrophysiology parameters (electroretinography (ERG), focal ERG
(fERG), and multifocal ERG (mfERG)), macular thickness measures, and intraocular pressure (IOP),
were included and reviewed in detail. Any discrepancies regarding inclusion of clinical studies were
resolved by consensus and, if necessary, discussion with a third author (JB). Table 1 presents the PICOS
(Population/Participants/Problem, Intervention, Comparators, Outcomes, Study Design) criteria that
were followed in order to identify clinical studies for the present review.
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Table 1. Predefined PICOS (Population/Participants/Problem, Intervention, Comparators, Outcomes,
Study Design) criteria that were followed in order to identify and include clinical studies in the
present review.
Parameters Descriptions
Population/Participants/Problem Adults with ocular disease
Intervention Any intervention with oral administration of saffron or one of itsconstituents
Comparison
Studies with any comparator/control that incorporated a
non-intervention group or studies with a pre- vs. post-intervention
comparison without a comparator/control group
Outcomes
Vision-related outcome measures, such as visual acuity, visual field
parameters, contrast sensitivity, electrophysiology parameters (ERG,
fERG, mfERG), macular thickness measures, and IOP
Setting Clinical studies/trials
ERG: electroretinography; fERG: focal electroretinography; mfERG: multifocal electroretinography; IOP:
intraocular pressure.
3. Clinical Evidence Regarding the Impact of Oral Supplementation with Saffron or One of Its
Constituents on Vision-Related Parameters in Adults with Ocular Diseases
Based on the results of the performed literature searches, there were eight published clinical
studies that have assessed the impact of oral supplementation with saffron or one of its constituents
on vision-related parameters in adults with ocular diseases [32–39]. Of these, six were randomized
controlled trials (RCTs) [32,35–39], while two are longitudinal interventional clinical studies reporting
on pre- (baseline) versus post-intervention comparisons without a comparator/control group [33,34].
For the two latter studies that are from the same group and report on different outcome measures, it is
also not clear whether their design involves, at least partly, participants of the same cohort, and efforts
to contact the corresponding authors in order to clarify this point were not successful [33,34]. The key
characteristics and findings of these eight clinical studies are presented in the following sections and
are summarized in Table 2.
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Table 2. Clinical studies investigating the effects of oral supplementation of saffron or crocin on vision-related parameters in adults with ocular diseases.
Ocular Disease Number ofSubjects
Constituent
Dosage Study Design Primary Outcome Measures—Findings
Proposed
Mechanisms Reference
AMD
[bilateral early
AMD]
N = 25 Saffron20 mg daily
Double-blind, placebo
controlled, cross over, RCT
three-month period with
cross over for another three
months
fERG: increased amplitude in saffron, but not in
placebo group
BCVA: increased (one line) in saffron, but not in
placebo group
Anti-oxidant
Neuroprotective
Falsini et al.
(2010) [32]
AMD
[bilateral early
AMD]
N = 29 Saffron20 mg daily
Longitudinal interventional
open-label study
three monthly follow-ups
over a 15-month period
fERG: increased amplitude that stabilized after
three months
BCVA: increased (two lines) that stabilized after
three months
Anti-oxidant
Neuroprotective
Piccardi et al.
(2012) [33]
AMD
[bilateral early
AMD]
N = 33 Saffron20 mg daily
Longitudinal,
3 monthly follow-ups over
a 12-month period
fERG: increased amplitude and sensitivity
amplitude that stabilized after three months
independent of genotype
Anti-oxidant
Anti-inflammatory
Neuroprotective
Marangoni et
al. (2013) [34]
AMD
[dry and wet
AMD]
N = 40
Saffron
15 mg twice
daily
Placebo controlled, RCT
six-month period with
follow-ups at three and six
months
CMT: decreased in saffron and placebo groups
in wet AMD, but not in dry AMD
ERG: amplitude increased in the saffron group
(dry and wet AMD) compared to placebo after
three months, but not six months
Neuroprotective
Anti-depressant
Lashay et al.
(2016) [35]
AMD
[mild/moderate
dry AMD]
N = 54 Saffron50 mg daily
Placebo controlled, RCT
three months
CMT: unchanged
BCVA: increased (one line) in saffron, but not in
placebo group
CS: increased in saffron, but not in placebo
group
Anti-oxidant
Hemorheological
activity
Riazi et al.
(2017) [36]
AMD
[mild/moderate
AMD]
N = 96 Saffron20 mg daily
Double-blind, placebo
controlled, cross over, RCT
three months followed by
cross over into the other
arm for
three months
BCVA: increased in saffron group [and AREDS *
+ saffron], but not in placebo
mfERG response density: increased in
AREDS+saffron, but not in the saffron or
placebo group
mfERG latency: decreased in saffron group, but
not in placebo group
Anti-oxidant
Neuroprotective
Broadhead et
al. (2019) [37]
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Table 2. Cont.
Ocular Disease Number ofSubjects
Constituent
Dosage Study Design Primary Outcome Measures—Findings
Proposed
Mechanisms Reference
POAG
[clinically stable
POAG]
N = 34 Saffron30 mg daily
Double-blind, placebo
controlled RCT
1 month duration
1 month wash-out
IOP: reduction after three and four weeks
compared to placebo
IOP returned to pre-intervention levels after a
4-week wash out period
Antioxidant
Neuroprotective
Bonyadi et al.
(2014) [38]
DME
N = 60
(101 DME
eyes)
Crocin
5 mg or
15 mg daily
Double-masked, placebo
controlled, phase 2 RCT
3 months
CMT: significantly decreased after three months
compared to placebo only in the 15 mg group
BCVA: significantly improved after three
months compared to placebo only in the 15 mg
group
HbA1c and FBG: significantly decreased after
three months compared to placebo only in the
15 mg group
Anti-oxidant
Hemorheological
activity
Anti-inflammatory
Sepahi et al.
(2018) [39]
*: participants were requested to continue on any supplements (including AREDS-based therapies) they had been taking prior to this study. AMD: age related macular degeneration;
POAG: primary open angle glaucoma; DME: diabetic macular edema; RCT: randomized clinical trial; BCVA: best corrected visual acuity; AREDS: Age-Related Eye Disease Study;
CMT: central macular thickness; CS: contrast sensitivity; ERG: electroretinography; fERG: focal electroretinography; mfERG: multifocal electroretinography; IOP: intraocular pressure;
HbA1c: haemoglobin A1c; FBG: fasting blood glucose.
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Age related macular degeneration: six published clinical studies assessed vision-related parameters
in AMD patients under oral saffron supplementation (Table 2) [32–37]. Based on these, both objective
(ERG) and subjective measures (Snellen, LogMar, EDTRS charts) of visual acuity were shown to
significantly improve with all tested dosages of saffron (daily dose range: 20–50 mg), even after
short-term oral supplementation (e.g., three months) [32–37]. Central macular thickness (CMT) [35] and
contrast sensitivity (CS) [36] were also assessed in certain studies (Table 2), with the latter reportedly
increasing with saffron supplementation [36], whilst the former was shown to decrease only in wet,
but not dry AMD following saffron supplementation [35]. As the formulation, dosage, intervention
duration, test methods, and outcome measures varied across these six studies, a direct quantitative
comparison was not possible. Of note, longer-term data are currently available only from the two
non-RCT studies with oral saffron supplementation (20 mg daily) in patients with bilateral early
AMD over 12 and 15 months, respectively (Table 2) [33,34]. In these two longer studies, the noted
improvements were achieved within three months of oral saffron supplementation, after which the
gained functionality seemed to plateau [33,34].
Glaucoma: the only existing clinical study in patients with primary open angle glaucoma (POAG)
reported that oral saffron supplementation (30 mg daily for one month) can significantly reduce the IOP
after three weeks (Table 2) [38]. In this pilot double-blind, placebo controlled RCT, all participants had
stable POAG (verified by visual field and optic nerve head examinations) and were treated with topical
timolol 0.5% twice daily and dorzolamide 2% three times daily. Compared to placebo, the addition
of daily oral saffron supplementation for one month resulted in significantly decreased IOP after the
third week, but this effect reverted after a 4-week wash-out period [38].
Diabetic maculopathy: despite the alarmingly increasing T2DM prevalence, only one eligible RCT
was identified in patients with refractory diabetic maculopathy; it examined the effects of oral crocin
supplementation (5 mg or 15 mg daily) (Table 2) [39]. In this study, Sepahi et al. reported a decrease
in CMT that appeared dose dependent, showing significant reduction after three months of daily
oral crocin supplementation compared to placebo in the higher (15 mg), but not in the lower (5 mg)
dosage group [39]. Visual function, as measured by best corrected visual acuity (BCVA), was also
significantly improved only in the higher dosage group compared to placebo. Moreover, in addition
to the ocular findings, oral crocin supplementation significantly reduced HbA1c and fasting blood
glucose levels only with the higher dose. Interestingly, while the lower crocin dose did not induce
significant reductions compared to placebo, the study authors noted that this dose could clinically
improve CMT, BCVA, HbA1c, and fasting glycaemia [39].
4. Action Time-Course of Oral Saffron Supplementation
To date, there are limited data regarding the time-course of the effects of oral saffron
supplementation on visual-related parameters in patients with ocular diseases. From most of
the aforementioned published clinical studies (Table 2) [32–39], it appears that saturation of the
saffron-induced effect(s) is reached within a three-month period of oral supplementation. It is plausible
that this saturation can be reached earlier; however, this remains uncertain, since most of these studies
included testing at three-month intervals. Moreover, it is noteworthy that in a study utilizing a light
damage model of photoreceptor degeneration in rats, the protection noted with the applied daily dose
of saffron (1 mg/kg) was detectable at two days, increasing to 10 days [40].
5. Safety Profile of Oral Saffron Supplementation
A relatively limited number of studies have examined the toxicity of saffron [18,22,41–43].
According to in vivo studies, saffron has very low toxicity for doses of up to 1.5 gr per day, while toxic
effects have been documented for daily doses ≥5 gr, with a lethal dose of approximately 20 gr [44].
The side effects of saffron are partly attributed to its dye/coloured constituents, which can accumulate
in the skin, mucosas, and/or sclera mimicking icteric symptoms [44].
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Taking into account that toxic effects of saffron appear to require doses of grams per day, clinical
data from studies in healthy volunteers suggest that saffron and crocin in doses of milligrams per
day can be considered safe [45,46]. Indeed, a randomized, double-blind, placebo-controlled study
examining the safety of oral crocin supplementation (20 mg daily compared to placebo) in healthy
volunteers concluded that this was relatively safe within the one-month study period [45]. In this
short-term study, there were no major adverse events and no changes in the studied haematological,
biochemical, hormonal, and urinary parameters, except for decreasing amylase levels, mixed white
blood cells, and partial thromboplastin time after one month [45]. Saffron doses of 200 mg and 400 mg
for seven days were also shown to be relatively safe in another double-blind, placebo-controlled study
in healthy volunteers, with changes in haematological and biochemical parameters that were not
considered clinically important [46]. Notably, in this study, one female participant in each of the two
saffron groups exhibited abnormal uterine bleeding [46].
Furthermore, systematic review data from RCTs examining the effectiveness of saffron on
behavioural and psychological outcomes also support the safety of saffron supplementation, since in
all these studies there were no significant differences in adverse events between saffron and placebo
groups [47]. Nausea, sedation, appetite fluctuation, and headache were among the most common
adverse effects reported in these RCTs, which used saffron daily doses ranging from 20 mg to
400 mg (supplements containing additional compounds with putative synergistic effects were
also used in some of these RCTs) [47]. Similarly, a good safety profile has been reported in the
available clinical studies in patients with ocular conditions, most of whom had regular follow-up
that also included telephone calls and interviews to ensure compliance and monitor possible side
effects [32–39]. Indeed, these studies concluded that the applied dose regimens of saffron and crocin
were safe without significantly increased safety risk [32–39]. As such, the available clinical evidence
supports the safety of oral saffron supplementation; however, longer-term studies are still required
in order to comprehensively evaluate the long term safety profile of saffron and its constituents in
various conditions.
Overall, caution is currently advised regarding saffron supplementation in patients with renal
insufficiency or bleeding disorders, and in those on anti-coagulation treatment due to potential
inhibition of platelet aggregation [21,41]. Finally, saffron supplementation has also potential
emmenagogue and abortifacient effects [48]. In fact, saffron has been reportedly used for induction of
abortion (doses >10 gr) [41,44], with amounts higher than those used in foods (>5 gr) having uterine
stimulant effects; thus, it should be avoided during pregnancy [21].
6. Proposed Mechanisms/Pathways Mediating the Effects of Saffron and/or Its Constituents in
Ocular Diseases
Taking into account the underlying pathophysiology of AMD, diabetic retinopathy, and glaucoma,
improvements in the overall pro-inflammatory and oxidative stress load, as well as in the systemic
vascular/endothelial health, have the potential to also positively impact on ocular-related parameters.
Therefore, given the favourable effects of saffron and/or its constituents on multiple CVD-risk
factors and inflammation [23,24,27,28], it is highly plausible that the same underlying anti-oxidant,
anti-apoptotic, and anti-inflammatory mechanisms/pathways are also facilitating the noted positive
effects of oral saffron supplementation in ocular diseases (Figure 1). For example, reduced circulating
levels of glutathione (GSH; a key radical scavenger) have been shown in patients with POAG, leading
to increased oxidative stress [49]. Accordingly, a possible mechanistic pathway mediating the effects of
saffron and its constituents (crocin and crocetin; both anti-oxidant carotenoids) is considered to involve
increased GSH levels that protect against reactive oxygen species and apoptosis [23]. Similarly, crocin
and crocetin may also suppress the activation of pro-inflammatory pathways (e.g., the nuclear factor
kappa-B pathway) [23,50–52]. Furthermore, these two saffron constituents appear to enhance oxygen
diffusion [53], and improve ocular blood flow [54], factors that play an important role in diseases such
as AMD. Of note, pathways targeting not only oxidative stress and inflammation, but also endothelial
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function are also particularly relevant to glaucoma treatment and may mediate the effects of saffron
and/or its constituents in patients with glaucoma. Indeed, the trabecular meshwork, which constitutes
the target tissue of glaucoma in the anterior chamber, is comprised by endothelial-like cells, and is
sensitive to oxidative damage, since it lacks effective antioxidant mechanisms [55,56]. As such, the
trabecular meshwork is altered in most types of glaucoma, consequently increasing IOP [56], and may
be a target for the effects of saffron and/or its constituents in patients with glaucoma; however, further
research is required to clarify these potential mechanisms/effects. Finally, saffron and its constituents
have been shown to improve glycaemia by enhancing insulin sensitivity and preventing pancreatic
beta-cell failure [39,57], which in turn may improve diabetic retinopathy/maculopathy [39].
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the effects of saffron and/or its constituents (e.g., crocin) in various ocular diseases (e.g., age
related macular degeneration, primary open angle glaucoma, and diabetic retinopathy), including
anti-inflammatory, anti-oxidant, anti-apoptotic, neuroprotective, antidiabetic, anti-atherogenic,
and anti-hypertensive effects.
Moreover, a recent study by Corso et al. demonstrated that saffron can decrease ATP-induced
retinal cytotoxicity by targeting the P2X7 receptors [58]. As these receptors are found in both inner
and outer retinal cells, which are affected in neurodegenerative disorders such as AMD, this suggests
another potential mechanistic pathway via which saffron may protect against neurodegeneration [58].
This is also supported by data showing that saffron may protect photoreceptors against retinal stress,
maintaining both function and morphology in a mammalian retinal model after exposure to damaging
bright continuous light [59]. Laabich et al. have also shown that crocin protects retinal photoreceptors
against light-induced cell death in primary retinal cell cultures [60].
It should be also noted that the pharmacokinetic details regarding whether and which saffron
constituents/metabolites reach the various tissues after oral intake of saffron or one of its constituents
are not fully clarified yet. Therefore, the exact mechanisms by which saffron and/or its constituents
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act on the retina (particularly, on the photoreceptors and bipolar cells) remain to be further elucidated.
Indeed, differences in uptake and tissue distribution may further account for different underlying
pathways/mechanisms which can mediate the observed effects of oral saffron supplementation in
patients with ocular disease. For example, lutein is considered to exert protective effects against AMD
through its anti-oxidative properties and its accumulation in the macula acting as a blue light filter [61].
On the other hand, saffron and its constituents may improve ocular function more indirectly by
improving the aforementioned systemic CVD-risk factors through anti-inflammatory and anti-oxidant
effects [22,23,26–28,62].
Pharmacokinetic studies in rats have shown that after oral administration, crocin is largely
excreted from the gastro-intestinal tract, which also serves as an important site for crocin hydrolysis [63].
As such, orally administered crocin is hydrolysed to crocetin before intestinal absorption [41,64].
Furthermore, crocetin has been shown to be quickly absorbed after oral administration in mice,
with a short plasma half-life, resulting in rapid elimination without accumulation in the body [41].
Interestingly, the progress of saffron supplementation has been examined both in an animal model
with light-induced retinal degeneration and AMD patients [42]. Indeed, experiments in albino rats
under saffron treatment showed that crocetin was detectable in the collected blood samples [42].
However, there were no traces of saffron-related metabolites in any other examined tissue, with the
exception of degenerating retinas where modest amounts of crocins were found in 7 of the 15 tested
animals [42]. These findings suggest that crocins may be resynthesized from circulating crocetin,
which can reach the retina following blood-brain barrier damage, as also supported by the fact that
no crocin or crocetin metabolites were found in healthy retinas or other parts of the central nervous
system [42]. In addition, based on analyses of blood and urine samples (collected within two hours
after the morning saffron dose) from two AMD patients under saffron supplementation for over a year
and three healthy volunteers after two weeks under the same saffron dose (20 mg daily), crocetin was
consistently quantified in both blood and urine samples from the healthy volunteers, but not in those
from the AMD patients, suggesting that these metabolites are immediately absorbed and used [42].
In line with this, data from an open-label, single dose escalation study (single crocetin dose of 7.5, 15,
and 22.5 mg in one-week intervals) have also indicated that crocetin is absorbed more quickly than
other carotenoids (e.g., lutein) in healthy adults [65].
Finally, an increasing body of RCTs indicate that saffron may improve the effects and symptoms
of depression [47,66–68]. As depression may often affect patients with chronic diseases (e.g., with
AMD, diabetic retinopathy, or glaucoma) [35,69,70] in whom it may also reduce treatment adherence
(e.g., potentially lower adherence to glaucoma treatment, and, hence increase the glaucoma progression
risk) [70], it seems plausible to hypothesize that some of the benefits of oral saffron supplementation
in patients with ocular diseases may also have a component relating to the potential anti-depressive
effects of saffron and/or its constituents [35]. However, currently there is a paucity of clinical data
addressing this hypothesis that requires testing in the context of well-designed RCTs.
Overall, the majority of the data regarding the potential mechanisms/pathways mediating the
effects of saffron and/or its constituents in ocular diseases originate from either in vitro experiments
on human cell lines or animal models. These experiments/models allow the study of effects and
mechanistic pathways that may be otherwise inaccessible, but have obvious limitations regarding
their applicability to humans due to their nature (e.g., models involving light- or drug-induced ocular
damage), which also cannot fully account for the multifactorial and progressive nature of most ocular
diseases in humans. In addition, findings documented in clinical studies with saffron or its constituents
that relate to subjective measures of vision and quality of life indices cannot be replicated and further
tested in animal models. Thus, it becomes evident that translating and clarifying the evidence regarding
the underlying mechanisms/pathways induced by saffron and/or its constituents in ocular diseases in
humans requires additional data from both pre-clinical and clinical studies.
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7. Summary of the Literature
The existing clinical evidence suggests that oral supplementation with saffron or crocin may
have positive effects on various vision-related parameters in adults with AMD, POAG, and diabetic
maculopathy (Table 2) [32–39]. Moreover, the findings from these clinical studies support the good
safety profile of oral supplementation with saffron (range of tested daily doses: 20 to 50 mg) and
crocin (5 mg and 15 mg daily) in these patients, but long term safety data are still scarce. As such, it is
not possible to draw firm conclusions for evidence-based recommendations regarding oral saffron
supplementation from the clinical studies conducted so far, since the existing data are considered rather
limited, particularly regarding long term outcomes and for conditions other than AMD. In addition,
further research is also required to clarify the exact underlying mechanisms that mediate the noted
positive outcomes of oral saffron supplementation in ocular diseases. Based on the available data from
in vitro, animal, and human studies, it is currently considered that pleiotropic effects of saffron and/or
its constituents relating to anti-inflammatory and anti-oxidant pathways, as well as to improvements
in oxygen diffusion and ocular blood flow are likely to facilitate the documented benefits of saffron
supplementation in ocular diseases (Figure 1) [22,23,26–28,53,54,62].
8. Conclusions
Saffron supplementation appears to have promising potential as an effective and safe adjunct
therapy in certain ocular diseases [32–39,61]. It is important to highlight that nutritional/dietary
supplements (i.e., concentrated sources of vitamins and minerals and/or other substances with a
nutritional or physiological effect that are marketed in “dose” form, such as tablets, capsules, pills,
or liquids in measured doses) have to comply to certain national/international regulations [71,72].
Indeed, although such supplements are regulated as foods, these are subject to different regulations
compared to other foods and from drugs in order to protect consumers against potential health
risks from these products and the general public against potentially misleading information [72].
However, such regulations vary from country to country, despite certain shared existing regulatory
frameworks (e.g., the European Directive on Food Supplements) [71,72]. Particularly for saffron, it is
also noteworthy that its content may vary depending on the source [61]. In this context, it becomes
evident that there is still an unmet need for additional bioavailability and pharmacokinetic studies,
as well as well-designed, adequately powered and long term RCTs in order to form evidence-based
recommendations for the potential therapeutic role of oral saffron supplementation in ocular diseases.
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